Business Wire

Novaliq Names Renown International Experts to Inaugural Scientific Advisory Board

Del

Novaliq GmbH, a pharmaceutical company with a disruptive drug delivery platform to transform poorly soluble drugs into effective therapeutics for ophthalmology, announced today the appointment of several renown experts to its newly formed scientific advisory board (SAB). The newly appointed SAB will strategically advise and support Novaliq as it continues to develop and bring to market innovative therapies for a broad range of ophthalmic indications, including dry eye and glaucoma.

The initial members of the Novaliq SAB include:

  • Claus Cursiefen, M.D., Ph.D., FEBO, chairman and professor, Department of Ophthalmology, University of Cologne, Germany. Prof. Cursiefen’s expertise lies in corneal lymphangiogenesis and cellular immunity in inflammatory eye diseases; corneal transplantation and ocular surface reconstruction; and, dry eye disease. A board member of DFG Neuroscience (“Fachkollegium”) and of the Cornea Section of the German Ophthalmological Society (DOG), Prof. Cursiefen is an internationally recognized speaker and has authored or co-authored more than 300 scientific publications. Prof. Cursiefen is a member of prestigious Leopoldina and Speaker of the only DFG Research Unit in Ophthalmology (www.for2240.de).
  • Norbert Pfeiffer, M.D., Ph.D., chairman and director, Department of Ophthalmology, The University Hospital Mainz, Germany. Prof. Pfeiffer’s research has focused on elucidating important aspects of the diagnosis and treatment of glaucomatous disease combining both morphological and functional aspects, and introducing basic science methods into the clinical diagnosis and treatment of glaucoma. A member of several national and international societies, including the American Academy of Ophthalmology (AAO), the Association for Research in Vision and Ophthalmology (ARVO), and the prestigious Leopoldina, Prof. Pfeiffer has authored or co-authored more than 400 scientific presentations and was awarded several scientific prizes including the Galenus von Pergamon prize.
  • Michael E. Stern, Ph.D., chief scientific officer, ImmunEyez, LLC, Orange County, California. Formerly the principal scientist as well as the vice president of Inflammation Research Program at Allergan where he worked for more than 26 years, Dr. Stern’s focus has been on identifying novel mechanisms and drug targets for immune-based inflammatory diseases that affect the ocular surface. His research has been instrumental to understanding the immunopathogenesis of ocular inflammatory disease and has led to the identification of target specific therapeutics, including RESTASIS®, the first FDA approved therapy for the treatment of dry eye disease. Dr. Stern has authored or co-authored more than 300 scientific publications and abstracts, is on the editorial board of The Ocular Surface, Journal of Ocular Pharmacology and Therapeutics, and Investigative Ophthalmology and Visual Science. He has received many honors, including the Diaz Caneja Award and the International Ocular Surface Society Award.
  • Kazuo Tsubota, M.D., chairman and professor of Ophthalmology, Keio University School of Medicine, Tokyo, Japan and co-director of Health Science Laboratory, Keio University-Shonan Fujisawa Campus, Kanagawa, Japan. An expert in tear film and ocular surface disease, Prof. Tsubota is a member of several national and international societies, including AAO, ARVO, and the American Academy of Cataract & Refractive Surgery (ASCRS), TFOS, and is a founding and board member of Sjogren’s Syndrome Association and Dry Eye Research Group, both in Japan. Prof. Tsubota serves on several editorial boards, has received awards from several ophthalmic societies, and has authored or co-authored more than 700 scientific publications.

"We are pleased and honored to have four distinguished experts in cornea, dry eye and glaucoma joining Novaliq’s team of advisors,” said Bernhard Günther, managing director and CEO of Novaliq GmbH. “I am confident that their experience and background will prove to be invaluable as we move our dry eye and glaucoma drug candidates through clinical development and trials.”

About Novaliq – Novaliq GmbH, founded in 2007, is a Heidelberg based specialty pharmaceutical company focused on ophthalmology. Its mission is to transform poorly soluble drugs into effective ocular therapeutics for both the front and the back of the eye. Novaliq’s proprietary EyeSol® technology enhances the topical bio availability, stability and safety of traditionally insoluble or unstable drugs improving the delivery, efficacy and convenience of treatments for ocular surface diseases including dry eye through preservative free and multi dose formulations. Novaliq’s most advanced product is NovaTears® with CE-marking based on Novaliq’s proprietary EyeSol technology. NovaTears is marketed under the brand name EvoTears® in Europe. More on www.novaliq.com.

Contact information

Europe
Novaliq GmbH
Bernhard Günther, + 49 6221 502 5911
Managing Director, CEO
info@novaliq.de
or
Novaliq GmbH
Oliver Schlüter, PhD, + 49 6221 502 59155
Managing Director, CFO
info@novaliq.de
or
USA
Scotia Vision Consultants
Michael O’Rourke, + 1-813-323-1438
scotiavc@gmail.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Celltrion Receives Positive CHMP Opinion for Herzuma® for Trastuzumab Biosimilar15.12.2017 22:13Pressemelding

Celltrion, Inc. (KOSDAQ: 068270) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending that Herzuma® (trastuzumab biosimilar) be granted marketing authorization in the European Union (EU) for the treatment of patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification. The CHMP’s opinion will now be sent to the European Commission (EC) for final review. Herzuma® is a biosimilar to Herceptin®i, a breast cancer and gastric cancer treatment antibody biologic drug developed by Genentech and marketed by Roche. Herceptin® is a blockbuster drug which had worldwide sales of CHF 6.8 billionii (US$6.8 billion) in 2016, of which CHF 2.1 billioniii (US$2.1 billion) was in

Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease15.12.2017 12:34Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), in conjunction with the Committee for Advanced Therapies (CAT), has adopted a positive opinion recommending a marketing authorization (MA) for investigational compound Cx601 (darvadstrocel). Cx601 is expected to be indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.2 This recommendation marks the first allogeneic stem cell therapy to receive a positive CHMP opinion in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/201712

Bitcoin Romania and Twispay Announce Integration Partnership Providing Users with the Ability to Purchase Bitcoin with Bank Cards15.12.2017 12:21Pressemelding

Bitcoin Romania, leading Eastern European Bitcoin exchange & brokerage firm, and Twispay, Swiss-owned European payment processor and FinTech pioneer, today announced the availability of a payment integration that allows a global clientele to acquire Bitcoin and Ethereum cryptocurrencies using Visa and Mastercard bank cards. Unprecedented in Romania, this is one of the first East-Central European integration partnerships that allow consumers to use their cards to purchase cryptocurrency. Until recently, investors could only acquire cryptocurrencies through bank transfers and cash deposits, but the volatility of cryptocurrency markets dictates the need for additional operational flexibility. Investors require faster, safer, more reliable, and more comfortable ways to complete purchases. “One minute can make the difference between a million lost and a million earned. That is pr

Upon Conclusion of the Fourth Annual Forum for Promoting Peace in Muslim Societies, Scholars and Intellectuals Visit the Louvre Abu Dhabi Museum15.12.2017 11:38Pressemelding

A high-level delegation of dignitaries, scholars and intellectuals participating in the fourth annual Forum for Promoting Peace in Muslim Societies, visited the Louvre Abu Dhabi museum. The delegation was headed by H.E Mustafa Ceric, former Grand Mufti of Bosnia; alongside Sheikh Mohammad Mukhtar Ould Imbala, Head of Mauritania’s Fatwa & Grievances Supreme Council; H.E Amar Mirghani Hussein, Sudanese Minister of (religious) Guidance and Endowments; and H.E Salho Jay, Imam of the Juma Masjid in South Africa. The Forum was held in Abu Dhabi from 11-13 December 2017, with the participation of more than 700 scholars, intellectuals and religious dignitaries from around the world. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171215005255/en/ Group Photo of the Scholars and Intellectuals during their visit to the L

Kennedy Wilson Acquires 124-Unit Northbank Apartments in Dublin, Ireland for €45 Million15.12.2017 11:00Pressemelding

Global real estate investment company Kennedy Wilson (NYSE: KW) announces that it has acquired Northbank Apartments, a wholly-owned 124-unit apartment community in Dublin’s North Docks, for €45 million from Jarmar Properties Limited (In Receivership) acting through David Carson of Deloitte as Statutory Receiver, the lender being the National Asset Management Agency (“NAMA”). Situated in Dublin’s North Docks, Northbank is located just 50 meters from Kennedy Wilson’s existing 84-unit Liffey Trust apartments. The two buildings benefit from great transport links as the LUAS Red line is immediately adjacent connecting to Dublin’s city centre and main train stations in five minutes. “The successful acquisition of Northbank in such close proximity to our Liffey Trust asset allows us to leverage our existing presence and implement our value-add asset management strategy, including a

AML BitCoin Enters Phase II of ICO15.12.2017 09:00Pressemelding

NAC Foundation, LLC announces today that the initial coin offering for the AML BitCoin – the world’s only patent-pending compliant digital currency – has been extended for another month to accommodate a torrent of last minute, new coin purchasers and the demands of thousands of current owners of the coin, who have had difficulty navigating the process of establishing the specialized wallet required to hold the innovative digital currency. This second phase of the AML BitCoin initial coin offering will see an increase in the price of the coin, from US $1.00 to US $1.25. The company has already been contacted by prospective purchasers in the slightly higher priced Phase II, and anticipates a further price increase to US $1.50 within a week or two. HitBTC, one of the world’s largest and most active digital currency exchanges, was prepared to list the AML BitCoin for trading on

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom